{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:09:54Z","timestamp":1778490594209,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uveal melanoma is predominantly an adult malignancy, with Ireland reporting one of the highest incidence rates at 9.5 cases per million adults annually. Paediatric uveal melanoma is extremely rare, accounting for fewer than 1% to 2% of all uveal melanoma cases in published series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included all patients under 18 years of age diagnosed with uveal melanoma in Ireland between 2010 and 2024. Data were collected from medical records and included demographics, tumour location and dimensions, histopathology or cytology (where available), presence of metastasis, treatment modality, baseline and final visual acuity, intraocular pressure, and survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six Caucasian patients (five male, one female), aged 6 to 17 years, were identified. Tumour locations included five choroidal and one ciliochoroidal melanoma. Treatment modalities included enucleation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), plaque brachytherapy (two Ruthenium-106, one Iodine-125), and proton beam radiotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). Histopathological analysis was available in two cases, revealing one mixed cell type and one spindle B melanoma. Fine needle aspiration biopsy was performed in two patients. Mean follow-up was 30 months (median 24; range 12\u2013178). All cases remained metastasis-free at last follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This national case series highlights the rarity and clinical relevance of paediatric uveal melanoma. Outcomes have been favourable, but recent case clustering supports the need for international comparative data collection. Early diagnosis and appropriate treatment help preserve vision and reduce morbidity. Molecular profiling, where possible, may guide metastatic risk assessment. Further studies are needed to confirm international incidence trends.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04334-2","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:12:36Z","timestamp":1772028756000},"page":"1050-1056","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paediatric uveal melanoma in Ireland 2010 \u2013 2024: incidence, clinical features, management, and outcomes"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-7194","authenticated-orcid":false,"given":"Denis","family":"Nevrov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"O\u2019Riordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda","family":"Fadlelseed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"D\u2019Arcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquina Martinez","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Capra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Murtagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"4334_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/archopht.1951.01700020432007","volume":"46","author":"EB Spaeth","year":"1951","unstructured":"Spaeth EB. Ocular tumors: a study of incidence of the various types and their mortality rates. AMA Arch Ophthalmol. 1951;46:421\u20133. https:\/\/doi.org\/10.1001\/archopht.1951.01700020432007.","journal-title":"AMA Arch Ophthalmol"},{"key":"4334_CR2","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/bjophthalmol-2015-306810","volume":"99","author":"MT Andreoli","year":"2015","unstructured":"Andreoli MT, Mieler WF, Leiderman YI. Epidemiological trends in uveal melanoma. Br J Ophthalmol. 2015;99:1550\u20133. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-306810.","journal-title":"Br J Ophthalmol"},{"key":"4334_CR3","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.040.","journal-title":"Ophthalmology"},{"key":"4334_CR4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.2147\/OPTH.S142984","volume":"12","author":"MV Fry","year":"2018","unstructured":"Fry MV, Augsburger JJ, Hall J, Corr\u00eaa ZM. Posterior uveal melanoma in adolescents and children: current perspectives. Clin Ophthalmol. 2018;12:2205\u201312. https:\/\/doi.org\/10.2147\/OPTH.S142984.","journal-title":"Clin Ophthalmol"},{"key":"4334_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/iovs.65.4.12","volume":"65","author":"NM van Poppelen","year":"2024","unstructured":"van Poppelen NM, Cassoux N, Turunen JA, Naus NC, Verdijk RM, Vaarwater J, et al. The pediatric and young adult choroidal and ciliary body melanoma genetic study, a survey by the European ophthalmic oncology group. Investig Ophthalmol Vis Sci. 2024;65:12 https:\/\/doi.org\/10.1167\/iovs.65.4.12.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4334_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.sjopt.2013.06.013","volume":"27","author":"CL Shields","year":"2013","unstructured":"Shields CL, Kaliki S, Arepalli S, Atalay HT, Manjandavida FP, Pieretti G, et al. Uveal melanoma in children and teenagers. Saudi J Ophthalmol. 2013;27:197\u2013201. https:\/\/doi.org\/10.1016\/j.sjopt.2013.06.013.","journal-title":"Saudi J Ophthalmol"},{"key":"4334_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","volume":"32","author":"CL Shields","year":"2012","unstructured":"Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363\u201372. https:\/\/doi.org\/10.1097\/IAE.0b013e31824d09a8.","journal-title":"Retina"},{"key":"4334_CR8","doi-asserted-by":"publisher","first-page":"e0144562","DOI":"10.1371\/journal.pone.0144562","volume":"10","author":"YM Liu","year":"2015","unstructured":"Liu YM, Li Y, Wei WB, Xu X, Jonas JB. Clinical characteristics of 582 patients with uveal melanoma in China. PLoS ONE. 2015;10:e0144562 https:\/\/doi.org\/10.1371\/journal.pone.0144562.","journal-title":"PLoS ONE"},{"key":"4334_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2013.11.006","volume":"18","author":"RT Al-Jamal","year":"2014","unstructured":"Al-Jamal RT, Kivel\u00e4 T. Uveal melanoma among Finnish children and young adults. J AAPOS. 2014;18:61\u20136. https:\/\/doi.org\/10.1016\/j.jaapos.2013.11.006.","journal-title":"J AAPOS"},{"key":"4334_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000492391","volume":"5","author":"C Baily","year":"2019","unstructured":"Baily C, O\u2019Neill V, Dunne M, Cunningham M, Gullo G, Kennedy S, et al. Uveal melanoma in Ireland. Ocul Oncol Pathol. 2019;5:195\u2013204. https:\/\/doi.org\/10.1159\/000492391.","journal-title":"Ocul Oncol Pathol"},{"key":"4334_CR11","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ophtha.2012.01.048","volume":"119","author":"EM Damato","year":"2012","unstructured":"Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2384 patients. Ophthalmology. 2012;119:1582\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2012.01.048.","journal-title":"Ophthalmology"},{"key":"4334_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","volume":"11","author":"BA Krantz","year":"2017","unstructured":"Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279\u201389. https:\/\/doi.org\/10.2147\/OPTH.S89591.","journal-title":"Clin Ophthalmol"},{"key":"4334_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.radcr.2021.09.064","volume":"17","author":"M Tsukikawa","year":"2021","unstructured":"Tsukikawa M, Akinpelu B, Wangaryattawanich P, Scherpelz K, Stacey AW. Uveal melanoma incidentally diagnosed with neuroimaging, a case series of 3 patients. Radiol Case Rep. 2021;17:54\u20139. https:\/\/doi.org\/10.1016\/j.radcr.2021.09.064.","journal-title":"Radiol Case Rep"},{"key":"4334_CR14","unstructured":"PDQ Pediatric Treatment Editorial Board. Childhood Intraocular (Uveal) Melanoma Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries [Internet]. 2024. National Cancer Institute (US). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK390611\/."},{"key":"4334_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/cancers17091403","volume":"17","author":"K Hanratty","year":"2025","unstructured":"Hanratty K, Finegan G, Rochfort KD, Kennedy S. Current Treatment of Uveal Melanoma. Cancers. 2025;17:1403 https:\/\/doi.org\/10.3390\/cancers17091403.","journal-title":"Cancers"},{"key":"4334_CR16","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/biomedicines12081758","volume":"12","author":"M Kulbay","year":"2024","unstructured":"Kulbay M, Marcotte E, Remtulla R, Lau THA, Paez-Escamilla M, Wu KY, et al. Uveal melanoma: comprehensive review of its pathophysiology, diagnosis, treatment, and future perspectives. Biomedicines. 2024;12:1758 https:\/\/doi.org\/10.3390\/biomedicines12081758.","journal-title":"Biomedicines"},{"key":"4334_CR17","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ophtha.2015.12.024","volume":"123","author":"RT Al-Jamal","year":"2016","unstructured":"Al-Jamal RT, Cassoux N, Desjardins L, Damato B, Konstantinidis L, Coupland SE, et al. The pediatric choroidal and ciliary body melanoma study: a survey by the european ophthalmic oncology group. Ophthalmology. 2016;123:898\u2013907. https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.024.","journal-title":"Ophthalmology"},{"key":"4334_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/PAS.0000000000002176","volume":"48","author":"S Kennedy","year":"2024","unstructured":"Kennedy S, Owens S, Ivers L, Hegarty C, O\u2019Neill V, Berenguer-Pina JJ, et al. Prognostic value of BAP1 protein expression in uveal melanoma. Am J Surg Pathol. 2024;48:329\u201336. https:\/\/doi.org\/10.1097\/PAS.0000000000002176.","journal-title":"Am J Surg Pathol"},{"key":"4334_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/cancers14010096","volume":"14","author":"NJ Lamas","year":"2021","unstructured":"Lamas NJ, Martel A, Nahon-Est\u00e8ve S, Goffinet S, Macocco A, Bertolotto C, et al. Prognostic biomarkers in uveal melanoma: the status Quo, recent advances and future directions. Cancers. 2021;14:96 https:\/\/doi.org\/10.3390\/cancers14010096.","journal-title":"Cancers"},{"key":"4334_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/0301-4738.154367","volume":"63","author":"S Kaliki","year":"2015","unstructured":"Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63:93\u2013102. https:\/\/doi.org\/10.4103\/0301-4738.154367.","journal-title":"Indian J Ophthalmol"},{"key":"4334_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/pcmr.12507","volume":"29","author":"A Tura","year":"2016","unstructured":"Tura A, Merz H, Reinsberg M, L\u00fcke M, Jager MJ, Grisanti S, et al. Analysis of monosomy-3 in immunomagnetically isolated circulating melanoma cells in uveal melanoma patients. Pigment Cell Melanoma Res. 2016;29:583\u20139. https:\/\/doi.org\/10.1111\/pcmr.12507.","journal-title":"Pigment Cell Melanoma Res"},{"key":"4334_CR22","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.3390\/cancers13215503","volume":"13","author":"RS Seedor","year":"2021","unstructured":"Seedor RS, Orloff M, Sato T. Genetic landscape and emerging therapies in uveal melanoma. Cancers. 2021;13:5503 https:\/\/doi.org\/10.3390\/cancers13215503.","journal-title":"Cancers"},{"key":"4334_CR23","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/s0140-6736(96)90736-9","volume":"347","author":"G Prescher","year":"1996","unstructured":"Prescher G, Bornfeld N, Hirche H, Horsthemke B, J\u00f6ckel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222\u20135. https:\/\/doi.org\/10.1016\/s0140-6736(96)90736-9.","journal-title":"Lancet"},{"key":"4334_CR24","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1167\/iovs.13-12195","volume":"54","author":"KG Ewens","year":"2013","unstructured":"Ewens KG, Kanetsky PA, Richards-Yutz J, Al-Dahmash S, De Luca MC, Bianciotto CG, et al. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Investig Ophthalmol Vis Sci. 2013;54:5721\u20139. https:\/\/doi.org\/10.1167\/iovs.13-12195.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4334_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40487-018-0056-8","volume":"6","author":"M Singh","year":"2018","unstructured":"Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther. 2018;6:87\u2013104. https:\/\/doi.org\/10.1007\/s40487-018-0056-8.","journal-title":"Oncol Ther"},{"key":"4334_CR26","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-10-2076","volume":"16","author":"B Damato","year":"2010","unstructured":"Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010;16:6083\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2076.","journal-title":"Clin Cancer Res"},{"key":"4334_CR27","unstructured":"Pilarski R, Byrne L, Carlo MI, Hanson H, Cebulla C, Abdel-Rahman M. BAP1 tumor predisposition syndrome. 2016 Oct 13 [updated 2024 Dec 5]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132025.27748099."},{"key":"4334_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ajo.2020.12.005","volume":"224","author":"N Singh","year":"2021","unstructured":"Singh N, Singh R, Bowen RC, Abdel-Rahman MH, Singh AD. Uveal Melanoma in BAP1 tumor predisposition syndrome: estimation of risk. Am J Ophthalmol. 2021;224:172\u20137. https:\/\/doi.org\/10.1016\/j.ajo.2020.12.005.","journal-title":"Am J Ophthalmol"},{"key":"4334_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.joco.2018.02.005","volume":"30","author":"B Masoomian","year":"2018","unstructured":"Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018;30:102\u20139. https:\/\/doi.org\/10.1016\/j.joco.2018.02.005.","journal-title":"J Curr Ophthalmol"},{"key":"4334_CR30","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/hmg\/ddz076","volume":"28","author":"P Repo","year":"2019","unstructured":"Repo P, J\u00e4rvinen RS, J\u00e4ntti JE, Markkinen S, T\u00e4ll M, Raivio V, et al. Population-based analysis of BAP1 germline variations in patients with uveal melanoma. Hum Mol Genet. 2019;28:2415\u201326. https:\/\/doi.org\/10.1093\/hmg\/ddz076.","journal-title":"Hum Mol Genet"},{"key":"4334_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/gcc.22424","volume":"56","author":"K Rai","year":"2017","unstructured":"Rai K, Pilarski R, Boru G, Rehman M, Saqr AH, Massengill JB, et al. Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 2017;56:168\u201374. https:\/\/doi.org\/10.1002\/gcc.22424.","journal-title":"Genes Chromosomes Cancer"},{"key":"4334_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/CMR.0000000000000613","volume":"29","author":"PA Johansson","year":"2019","unstructured":"Johansson PA, Nathan V, Bourke LM, Palmer JM, Zhang T, Symmons J, et al. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. Melanoma Res. 2019;29:483\u201390. https:\/\/doi.org\/10.1097\/CMR.0000000000000613.","journal-title":"Melanoma Res"},{"key":"4334_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/jnci\/djad248","volume":"116","author":"MC Villy","year":"2024","unstructured":"Villy MC, Le Ven A, Le Mentec M, Masliah-Planchon J, Houy A, Bi\u00e8che I, et al. Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants. J Natl Cancer Inst. 2024;116:580\u20137. https:\/\/doi.org\/10.1093\/jnci\/djad248.","journal-title":"J Natl Cancer Inst"},{"key":"4334_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejca.2022.06.033","volume":"173","author":"M Saint-Ghislain","year":"2022","unstructured":"Saint-Ghislain M, Derrien AC, Geoffrois L, Gastaud L, Lesimple T, Negrier S, et al. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. Eur J Cancer. 2022;173:105\u201312. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.033.","journal-title":"Eur J Cancer"},{"key":"4334_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djaa047","volume":"113","author":"AC Derrien","year":"2021","unstructured":"Derrien AC, Rodrigues M, Eeckhoutte A, Dayot S, Houy A, Mobuchon L, et al. Germline MBD4 mutations and predisposition to uveal melanoma. J Natl Cancer Inst. 2021;113:80\u20137. https:\/\/doi.org\/10.1093\/jnci\/djaa047.","journal-title":"J Natl Cancer Inst"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04334-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04334-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04334-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:29:01Z","timestamp":1778488141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04334-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4334"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04334-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Noel Horgan is a member of the\n                      Eye\n                      editorial board. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}